Trastuzumab deruxtecan belongs to a group of antineoplastic drugs known as antibody-drug conjugates (ADCs). This type of ...

The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment ...

NeoGenomics announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) ...

Shares of Instil Bio climbed after the company shared progress on a trial in China for its non-small cell lung cancer treatment in combination with chemotherapy and said it is preparing to start U.S.

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Authors conducted a systematic literature review to gather evidence on the appropriateness of recommended treatments for locally advanced non–small cell lung cancer (LA-NSCLC) from the American ...

From trial phases to personalized care, here’s how healthcare providers can navigate cancer clinical trials and guide ...

Data to be presented at ASCO reflect Boehringer's broad pipeline and growing body of evidence supporting innovative therapies for various cancersPatient-reported outcomes from the Beamion LUNG-1 study ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

Bristol-Myers Squibb (NYSE:BMY) recently received European Commission approval for its Opdivo regimen in treating resectable ...

A Post-Treatment Blood Test Could Inform Future ... demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or ...